# q02 rev 0 - raw independent returns

tested_sha256: dbcdd1ab7a1f1f801fcaed614dff874ad77bb52ed030c8afb7b9d2cc3adc23dc
Date: 2026-10-05. Runtime: Claude Code (VS Code), fresh Agent-tool subagents (Opus 5.5), each given
only the workspace root, its own packet path and the frozen question (closed-book: question only).
Returns below are the agents' final reports as delivered, unedited.

## Closed-book (closed-book-solver, question text only)

answer: Q1 2025 (quarter ended March 31, 2025) is the only quarter I can confirm. Guidance was $1.05–$1.09 and the actual result was $1.09. The other 2025 quarters came in below the top of their ranges: Q2 2025 was $1.26 against $1.23–$1.27, Q3 2025 was $1.30 against $1.28–$1.32, and Q4 2025 was $1.50 against about $1.47–$1.53. I can't say for Q1 2026 or Q2 2026.

confidence: medium

basis: From memory of Abbott's quarterly earnings releases and guidance. I'm not sure of the Q1 2026 result, and Q2 2026 results came out after my knowledge cutoff, so either 2026 quarter could have hit the top of its range.

contaminated: no

## Solver A (blind-solver, packet solver-1)

I didn't read question.txt or anything outside the packet's text/ and docs/ folders.

answer: The quarter ended March 31, 2025 (Q1 2025) and the quarter ended June 30, 2026 (Q2 2026).

confidence: high

path:
1. **Q1 2025: match.**
   - Range: D01 (Jan 22, 2025), guidance section p.7, line 319: "first-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09."
   - Actual: D02 (Apr 16, 2025), line 17: "adjusted diluted EPS of $1.09". The p.9 table shows "$1.09 $0.98". D08 line 277 repeats 1Q25 as $1.09.
   - $1.09 equals the top of the range.
2. **Q2 2025: no match.**
   - Range: D02 line 201: "second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27."
   - Actual: D03 (Jul 17, 2025), line 17: "adjusted diluted EPS of $1.26". D10 line 365 repeats 2Q25 as $1.26.
   - $1.26 is one cent below the top.
3. **Q3 2025: no match.**
   - Range: D03 line 299: "third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32."
   - Actual: D04 (Oct 15, 2025), line 17: "adjusted diluted EPS of $1.30". That is the midpoint.
4. **Q4 2025: no explicit range, so excluded.**
   - D04 gives only a full-year figure. Line 287: "narrows the range to $5.12 to $5.18". It has no fourth-quarter range.
   - A search of all docs/ for quarterly EPS ranges found six. None is for Q4 2025.
   - Actual: D07 (Jan 22, 2026), line 17: "adjusted diluted EPS of $1.50".
5. **Q1 2026: no match.**
   - Range: D07 line 283: "first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18."
   - Actual: D08 (Apr 16, 2026), line 17: "adjusted diluted EPS of $1.15". That is the midpoint.
6. **Q2 2026: match.**
   - Range: D08 line 205: "Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31."
   - Actual: D10 (Jul 16, 2026), line 17: "adjusted diluted EPS of $1.31". The p.9 table shows "$1.31 $1.26 4.0".
   - $1.31 equals the top of the range.
7. **Later filings do not change Q2 2026.**
   - The Q3 2026 range in D10 ($1.38 to $1.46) is outside the window.
   - No document between D08 and D10 revises the Q2 2026 range: D09 is a litigation notice.
   - No document restates a quarter's adjusted EPS. D11 (Aug 20, 2026) is a litigation settlement release.
8. **Cross-check.** All decisive lines above match exactly in the original docs/ files.

minimal_documents:
- **Full answer, including the exclusions:** D01, D02, D03, D04, D07, D08, D10.
- **The two matches alone:** D01, D08 and D10 are enough, because D08's comparison column prints the Q1 2025 actual of $1.09.
- **Not needed:** D05 (Exact Sciences deal), D06 (By-Laws), D09 and D11 contain no EPS guidance or results.

readings:
- **Implied Q4 2025 range.** Subtracting the nine-month adjusted EPS of $3.65 (D04 p.11) from the narrowed full-year range gives:
  - $5.12 − $3.65 = $1.47 and $5.18 − $3.65 = $1.53.
  - The actual $1.50 is not at the top, so the answer is unchanged.
  - The July full-year range ($5.10 to $5.20) implies $1.45 to $1.55, and the January range ($5.05 to $5.25) implies $1.40 to $1.60. The answer is still unchanged.
- **"At or above the top."** No quarter beat its top, so the answer is the same.

gaps:
- **Extraction gaps.** The text/ files have "[... N characters not shown ...]" gaps in some table rows. None touches a guidance sentence or an adjusted-EPS line, and the docs/ originals confirm those lines.
- **D06 partly read.** D06 (By-Laws, about 115K characters) was read for its first 80 lines only. Searches of it for "quarter", "per share", dollar amounts, "EPS", "guidance" and "outlook" found nothing.
- **No page images.** The manifest lists no PDF pages, so there were none to inspect.

contaminated: no

Files used:
- D:\Dev\Docket\tasks\aq-00745\runs\q02-r0-v2-dbcdd1ab7a1f1f801fcaed614dff874ad77bb52ed030c8afb7b9d2cc3adc23dc\solver-1\text\D01.txt, D02.txt, D03.txt, D04.txt, D07.txt, D08.txt, D10.txt
- D:\Dev\Docket\tasks\aq-00745\runs\q02-r0-v2-dbcdd1ab7a1f1f801fcaed614dff874ad77bb52ed030c8afb7b9d2cc3adc23dc\solver-1\docs\ (originals used for the cross-check)

## Solver B (blind-solver, packet solver-2)

**Answer:** Two quarters met the top of their projected range: the quarter ended March 31, 2025 (Q1 2025) and the quarter ended June 30, 2026 (Q2 2026). Every other quarter landed at or below the middle of its range.

answer: The quarter ended March 31, 2025 (Q1 2025: $1.09 vs. a $1.05–$1.09 range), and the quarter ended June 30, 2026 (Q2 2026: $1.31 vs. a $1.25–$1.31 range)

confidence: high

path:
1. **Q1 2025 — match.**
   - Range: D01 (Jan 22, 2025), Guidance section, p.7 says "first-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09."
   - Actual: D02, p.1 says "adjusted diluted EPS of $1.09." The p.9 table also shows $1.09.
   - D08 p.9 repeats $1.09 for 1Q25 as its prior-year comparison.
   - $1.09 equals the top.
2. **Q2 2025 — no.**
   - Range: D02 p.7 says "second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27."
   - Actual: D03 p.1 says "adjusted diluted EPS of $1.26." D10's prior-year column also shows $1.26.
   - $1.26 is below $1.27.
3. **Q3 2025 — no.**
   - Range: D03 p.7 says "third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32."
   - Actual: D04 p.1 says "adjusted diluted EPS of $1.30," which is the midpoint.
4. **Q4 2025 — no quarterly range was published.**
   - D04 p.7 gives only a full-year figure: it "narrows the range to $5.12 to $5.18."
   - Searching all documents for "[first/second/third/fourth]-quarter 20xx adjusted diluted" finds only Q1'25, Q2'25, Q3'25, Q1'26, Q2'26 and Q3'26 ranges.
   - Actual: D07 p.1 says "adjusted diluted EPS of $1.50."
   - Implied range: D04 p.10 shows 9M25 adjusted EPS of $3.65. So $5.12 − $3.65 = $1.47 and $5.18 − $3.65 = $1.53, and $1.50 is the midpoint.
   - Check: $3.65 + $1.50 = $5.15, which matches the full-year actual in D07 ("adjusted diluted EPS of $5.15").
5. **Q1 2026 — no.**
   - Range: D07 p.7 says "first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18."
   - Actual: D08 p.1 says "adjusted diluted EPS of $1.15," the midpoint.
6. **Q2 2026 — match.**
   - Range: D08 (Apr 16, 2026) p.7 says "Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31."
   - Actual: D10 (Jul 16, 2026) p.1 says "adjusted diluted EPS of $1.31." The p.9 table shows "$1.31 $1.26."
   - $1.31 equals the top.
   - Nothing changed this in between. D09 (Apr 17, 2026) is a shareholder lawsuit settlement notice, and D11 (Aug 20, 2026) announces a litigation settlement after the results; neither revises guidance or results.
7. **Irrelevant documents.** D05 is the Exact Sciences acquisition release and has no EPS guidance; its only related claim is "accretive to … revenue growth and gross margin." D06 is the By-Laws: a search for guidance, outlook, EPS or quarter terms found nothing, while a control search found 106 hits for "Corporation."

minimal_documents: D01, D02, D03, D04, D07, D08, D10.
- The Q1'25 actual could come from D08 instead, but D02 is still needed for the Q2'25 range.
- The Q2'25 actual could come from D10 instead, but D03 is still needed for the Q3'25 range.
- The Q3'25 actual can be derived as D07 FY $5.15 − Q4 $1.50 − D03 1H $2.35 = $1.30. D04 is still needed to show there was no Q4 range.
- The two matches alone need only D01 + D02 (or D08), and D08 + D10.

readings:
- **Implied Q4 2025 range from full-year guidance:** $1.47–$1.53 (October), $1.45–$1.55 (July range $5.10–$5.20) or $1.40–$1.60 (January range $5.05–$5.25). $1.50 is never the top, so the answer is unchanged.
- **"Met or exceeded the top":** no quarter beat its top, so the answer is unchanged.
- **"In advance" meaning before the quarter began:** every quarterly range was issued after its quarter started (Jan 22, Apr 16 and Jul 17 releases), which would make the answer "none." This is not the ordinary meaning, which is before the results were known.

gaps:
- There is no explicit Q4 2025 quarterly range in the packet.
- Both the text/ and docs/ sources contain "[... N characters not shown on the page ...]" gaps. They hide sales-growth rows, income-statement top lines and specified-item rows, but not the EPS lines used here.
- There are no PDFs or layout files, so original pages could not be checked.
- D06 was read only to line 120. Whole-file searches covered the rest.
- The docs/ files were searched but not read in full; they match the text/ content seen.

contaminated: no

Packet: D:\Dev\Docket\tasks\aq-00745\runs\q02-r0-v2-dbcdd1ab7a1f1f801fcaed614dff874ad77bb52ed030c8afb7b9d2cc3adc23dc\solver-2\text\ (D01.txt–D11.txt)

## Shortcut audit (shortcut-auditor, packet shortcut)

I found two quarters where adjusted diluted EPS equalled the top of the range Abbott had projected in advance: Q1 2025 and Q2 2026. There is no single-document shortcut.

answer: The quarter ended March 31, 2025 ($1.09, against a projected $1.05 to $1.09) and the quarter ended June 30, 2026 ($1.31, against a projected $1.25 to $1.31).

verdict: clear

shortest_path:

| Quarter | Range projected in advance (source) | Actual adjusted diluted EPS (source) | Equals top? |
|---|---|---|---|
| Q1 2025 | $1.05 to $1.09 (D01, Jan 22, 2025, line 319) | $1.09 (D02 lines 17/269; also D08's prior-year column, "$1.15 $1.09") | Yes |
| Q2 2025 | $1.23 to $1.27 (D02 line 201) | $1.26 (D03 lines 17/369; also D10's prior-year column) | No |
| Q3 2025 | $1.28 to $1.32 (D03 line 299) | $1.30 (D04 lines 17/355) | No |
| Q4 2025 | No quarterly range given (D04 lines 285–289) | $1.50 (D07 lines 17/357) | No |
| Q1 2026 | $1.12 to $1.18 (D07 line 283) | $1.15 (D08 lines 17/277) | No |
| Q2 2026 | $1.25 to $1.31 (D08, Apr 16, 2026, line 205) | $1.31 (D10 lines 17/365) | Yes |

- The Q1 2025 guidance reads: "Abbott projects … first-quarter 2025 adjusted diluted earnings per share of $1.05 to $1.09."
- The Q2 2026 guidance reads: "Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31."
- For Q4 2025, D04 only narrowed the full-year range to $5.12–$5.18. Subtracting nine-month EPS of $3.65 (D04 line 391) implies $1.47 to $1.53. Using the older full-year range of $5.10–$5.20 (D03) minus H1 $2.35 minus Q3 $1.30 implies $1.45 to $1.55. Either way $1.50 is the midpoint, not the top.
- The figures reconcile. H1 2026 is 1.15 + 1.31 = $2.46 (D10 line 411). H1 2025 is 1.09 + 1.26 = $2.35 (D03 line 411). Full-year 2025 is 3.65 + 1.50 = $5.15 (D07 line 409).

sufficient_documents: D01, D02, D03, D04, D07, D08 and D10 are all needed. They supply the guidance for each quarter in turn, plus Q3 2025 (D04), Q4 2025 (D07) and Q2 2026 (D10) actuals. There are some alternatives for the actuals only:
- Q1 2025 actual: D02 or D08's prior-year column.
- Q2 2025 actual: D03 or D10's prior-year column.
- Q1 2026 actual: D08, or D10's H1 figure minus Q2 ($2.46 − $1.31).

No release reports the projected range for the quarter it covers, and none says results hit the "top" of guidance. D05 (Exact Sciences deal announcement), D06 (By-Laws), D09 (derivative settlement notice) and D11 (preterm formula litigation settlement) are distractors.

searches:
- Text terms: guidance, projects/projected, range of, forecast, outlook, expects; "adjusted diluted EPS/earnings per share"; the earnings-statement line "Diluted Earnings per Common Share, excluding Specified Items"; upper end, top of, high end, exceed, beat, aligned with, achieved.
- Original docs/: "quarter 202[56] adjusted diluted…" and "fourth-quarter 2025".
- Read D04, D09 and D11 in full, the openings of D06, D08 and D10, and D07's guidance section. Checked D05 and D06 for EPS terms; there were none relevant.
- All 11 documents are covered. The only "upper end" statement is D01's comment on full-year 2024, which is out of scope.

readings/gaps:
- **Q4 2025:** Read strictly, Q4 2025 had no projected range and drops out. Read as an implied range, it still misses. The answer is the same either way.
- **Exact Sciences close:** The deal closed March 23, 2026. The packet shows no revised Q1 2026 guidance, and Q1 2026 misses regardless. Nothing in the packet updates the Q2 2026 range between April 16 and June 30, 2026.
- **Extraction gaps:** 121 "[... not shown on the page ...]" markers appear in the original files themselves, all in table rows. None touch the guidance sections or the EPS lines used here.
- **Difficulty risk, not a shortcut:** All quarterly ranges share one phrasing, so two greps plus a comparison per quarter solve it. That route is a valid cross-document join.
- **Contamination:** None seen. I did not open question.txt, notes or other packets, and no key, author reasoning or project memory was present. I cannot check the launcher's invocation mode myself.

Files are under D:\Dev\Docket\tasks\aq-00745\runs\q02-r0-v2-dbcdd1ab7a1f1f801fcaed614dff874ad77bb52ed030c8afb7b9d2cc3adc23dc\shortcut\:
- text\D01.txt
- text\D02.txt
- text\D03.txt
- text\D04.txt
- text\D07.txt
- text\D08.txt
- text\D10.txt
